Nysestock-news.com Website Review

transenterix (trxc): a futile business with fake surgeries attracts billions to its execs. The news of transenterix receiving fda clearance for diameter instruments has perked the market . However, that is an. Old suggestion. And allegedly aimed at diluting the $100m ditch that transenterix management are currently performing. So can a. reverse-merged (2013), surgical robot firm firm like transenterix with only $3.5 million in earnings in qi 2018 -- possibly. Be worth a lot more than $ 1billion? The only logical answer is that there are no real surgeries behind it (and we'll prove it further). the. Organization that is whole is a inch billion joke created for the execs to flourish to the trxc value rising and down. Let's believe six main conditions that we point as reasons for the trxc stock to shed weight. But before we jump into it, here is the ugly. Another fraud caused a billionaire investor, by phillip suspend. A notorious healthcare investor. Sec has charged mr frost for making money. Along with ten firms that were as*ociated and additional ten individuals, phillip frost was proved to have generated more than $27 million in 2013-2018 through misinforming articles and trading. Recently, phillip freeze sold almost $23 million of trxc. Nothing new though has been known for the rallies resulting in stock reductions and insider selling. Some basic maths. Only 2 senhance surgical procedures were sold by transenterix in the united states. Only 2, which is the half of all systems nearly one year ago, november 20 17, florida hospital orlando, teaching hospital at the superior rank, was the first to install one of senhance medcare pros believe senhance system'a bit of junk'. For specialists, the senhance surgical robot of trxc has some flaws which deter it out of the vast adoption. Thus it's sometimes and chiefly employed for training reasons -- clinically. Side-by-side clinical studies from this trxc's robots reveal inferior results compared to the standard laparoscopy.